Saizen + Saizen
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Growth Hormone Deficiency
Conditions
Growth Hormone Deficiency, Turner Syndrome
Trial Timeline
May 31, 2005 → Sep 30, 2007
NCT ID
NCT00256126About Saizen + Saizen
Saizen + Saizen is a approved stage product being developed by Merck for Growth Hormone Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00256126. Target conditions include Growth Hormone Deficiency, Turner Syndrome.
What happened to similar drugs?
10 of 20 similar drugs in Growth Hormone Deficiency were approved
Approved (10) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00256126 | Approved | Completed |
Competing Products
20 competing products in Growth Hormone Deficiency